limited on the products, whose technical characteristics can be described in advance, characteristic thatmakes it with difficulty to apply to most products which were not still developed. (2) Hollis (2005a, B) anOptional reward plan suggested, in which enterprises could decide to offer an opened license for medicine for neglected diseases as reconciliation for a payment of reward capital in which the payment would be based on the health effect of the authorized drug. (3) suggest the project BioShield II act of 2005 in the United States that companies, which develop drugs for certain diseases should reach one „Wildcard “patent extension for another drug in the United States. Paper supplements itself to chapters 5 by bricklayers in this book and chapters 6 by Sloan and Eesley.Maurer takes broader perspective and compares, which it refers „sequential “solutions (as those, which I examine here) calls, with „pay-point-IE-gone “initiatives, in which government or other financing at much promising research or at clinical studies, how uses. Bricklayers argued that sequential solutions, because they impose upon larger risk to private enterprises, than can be more expensive pay-point-IE-go plans. However sequential plans have very attractive spurring characteristics, because them developingimportant success in drugs recompense. SloanandEesley discuss expenditures for implementation of an institute of the medicine request for advanced purchases of the vaccines in the United States. I begin with a short examination of the neglected diseases. I define neglected illness, since one, on which on research spent additional dollar, would have a relatively large increase effect on therapeutic results. Drogenfirme, because of their obligations to the shareholders, invest in developing therapies for the diseases, which are based on the increase effect on profits. This means that neglected diseases those is expected to be unprofitable for the investment, in order despite the opportunity for improving the therapeutic results is. Other $200 million in the research into an already heavily investigated illness to invest can be useful, and froma profit perspective, can it the right thing be to do to; but it is probable that of the perspective of the maximization of the number and the quality of the human life on the planet, it could be more useful to spend the money on developing treatments on malaria. It is this direction, in which malaria neglected one „“illness is. In reality such diseases those, which are mainly predominant in with low the income countries, are natural. Table 4.1 shows diseases according to the entire „disabilityadjusted life years “(healthy years of life) lost to each illness or on condition. (A healthy year of life is a standardised measure of results of health.) Some diseases are grouped together for comfort. The PAPER is complementary tons of Chapter of 5 by bricklayers in this book and Chapter 6 by Sloan and Eesley.Maurer of takes A against perspective, comparing what he calls “END-ton-ends” solutions (look for as the ones I examine here) with “pay as you go” initiatives in which government or more other funding is directing RK promising research or clinical trias as needed. Bricklayers of argues that END-ton-end solutions, because they impose more greater risk on private firms, May fuel element more expensive than pay as you go plan. However, END-ton-end plan have very attractive incentive properties because they reward success in developingimportant drugs. SloanandEesley discuss implementation of issues OF to institutes OF Medicine proposal for advanced purchases OF of vaccines into the United States. I begin with A letter examination OF neglected diseases. I DEFINE A neglected disease as one for which additional dollars spent on research would have A relatively large Inc. rem valley impact on therapeutic outcomes. Drug of companies, because OF their obligation tons shareholders, invest into developing therapies for diseases based on the Inc. rem valley effect on of profit. This means that neglected diseases of acres those for which investment is expected tons of fuel element unprofitable, the pits the opportunity for improving therapeutic outcomes. Investing more another $200 million into research into on already heavily researched disease May fuel element useful, and froma profit perspective, it May fuel element the right thing tons of DO; but it is likely from the perspective OF maximizing the NUMBERs if and quality OF of humanly lives on the planet that, it might fuel element more useful ton donate the money on developing treatments for to malaria. It is this scythe in which malaria is A “neglected” disease. In effect, OF course, look for diseases of acres the ones primarily prevalent into lowincome countries. Figure 4,1 shows diseases according tons totally “disabilityadjusted life years” (DALYs) draws ton each disease or condition. (A DALY is A standardized measure OF health outcomes.) Some of diseases of acres grouped more together for convenience.